Assessing Hologic: Insights From 10 Financial Analysts
Portfolio Pulse from Benzinga Insights
Hologic (NASDAQ:HOLX) has received mixed ratings from 10 analysts over the past three months, with a slight increase in the average 12-month price target to $86.6. Analysts have adjusted their ratings and price targets, reflecting evolving market conditions and company performance. Hologic's financial performance shows strong net margins and return on equity, but its revenue growth lags behind industry peers.
October 04, 2024 | 6:03 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Hologic has received mixed analyst ratings, with a slight increase in the average 12-month price target to $86.6. Analysts have adjusted their ratings and price targets, reflecting evolving market conditions and company performance. Hologic's financial performance shows strong net margins and return on equity, but its revenue growth lags behind industry peers.
The mixed analyst ratings and slight increase in price target suggest a neutral short-term impact on Hologic's stock price. The company's strong financial metrics like net margins and ROE are positive, but the lagging revenue growth compared to peers tempers the outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100